207TiPA phase I/II trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr Virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies. (25th November 2018) - Liu, B; Yan, J; Su, S; Shao, J; Zhao, Y; Xu, Q; Yang, Y; Zou, Z; Huang, X; Wei, J